

ASX RELEASE

8 September 2025

Change of Director's Interest Notice – Appendix 3Y: Jane Bell

Appendix 3Y Change of Director's Interest Notice for Mrs. Jane Bell is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx)

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	AMPLIA THERAPEUTICS LIMITED
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jane Catherine Bell
Date of last notice	20 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	1 September 2025 re Allotment of Shares and Options 6 September 2025 re Expiry of Options
No. of securities held prior to change	Mrs Jane Catherine Bell 485,036 Ordinary Shares Mrs Jane Catherine Bell & Mr Geoffrey Bell <Schooner Super Fund A/C> 3,046,280 Ordinary Shares 535,000 Unlisted Options Ex Price \$0.26 Exp 6 Sep 2025 521,739 Listed Options Ex Price \$0.1725 Exp 31 Oct 2027
Class	a. Ordinary Shares b. Options Ex Price \$0.30 Expire 30 Sep 2028 c. Options Ex Price \$0.2533 Expire 6 Sep 2025

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<ul style="list-style-type: none"> a. 130,435 Ordinary Shares b. 240,590 Options Ex Price \$0.30 Exp 30 Sep 2028
Number disposed	<ul style="list-style-type: none"> c. 535,000 Unlisted Options Ex Price \$0.26 Exp 6 Sep 2025
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ul style="list-style-type: none"> a. Participation in Capital Raise – Director Placement Shares \$0.23 per share following approval by shareholders at AGM held 27 August 2025 b. Allotment of Options for Nil Consideration following approval by shareholders at AGM held 27 August 2025 c. Expiry of Options – not exercised, nil consideration
No. of securities held after change	<p>Mrs Jane Catherine Bell 485,036 Ordinary Shares</p> <p>Mrs Jane Catherine Bell & Mr Geoffrey Bell <Schooner Super Fund A/C> 3,176,715 Ordinary Shares</p> <p>240,590 Unlisted Options Ex Price \$0.30 Exp 30 Sep 2028</p> <p>521,739 Listed Options Ex Price \$0.1725 Exp 31 Oct 2027</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ul style="list-style-type: none"> a. Participation in Capital Raise – Director Placement Shares as approved by shareholders at AGM held 27 August 2025. b. Allotment of Options for Nil Consideration following approval by shareholders at AGM held 27 August 2025 c. Expiry of Options – not exercised, nil consideration

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

8 September 2025

+ See chapter 19 for defined terms.

For personal use only